

## POWER OF ATTORNEY

As shareholder(s) of **Marinomed Biotech AG**, I/we hereby authorize

### Mr. Florian PRISCHL

c/o IVA – Interessenverband für Anleger, Feldmühlgasse 22, 1130 Vienna, Austria

to represent me/us at the **Extraordinary General Meeting of Marinomed Biotech AG**, FN 276819 m, to be held on **23 September 2025, at 1:00 p.m. (Vienna time)**, as shareholder(s) and to exercise all rights to which I am/we are entitled as shareholder(s) of Marinomed Biotech AG, including, but not limited to the voting right.

In particular, I/we authorize the above-mentioned proxy holder to vote on my/our behalf and pass resolutions regarding the following **agenda items**:

1. Resolution on (a) the cancellation of the authorization to issue financial instruments within the meaning of Section 174 AktG resolved at the Extraordinary General Meeting on 19 December 2024 under item 2 of the agenda and (b) the authorization of the Management Board, with the approval of the Supervisory Board, to issue financial instruments within the meaning of Section 174 AktG, in particular convertible bonds, participating bonds or profit participation rights, which may provide for the subscription and/or exchange of shares in the company, whereby the subscription rights of shareholders to these financial instruments are excluded (direct exclusion of subscription rights)
2. Resolution on the conditional increase of the company's share capital pursuant to Section 159 para. 2 no. 1 AktG for the issue to creditors of financial instruments ("Conditional Capital 2025") and the corresponding amendment of the Articles of Association in Section 5 (Share Capital and Shares)

I/we issue the instruction to the above mentioned proxy holder to vote on my/our behalf regarding the resolution proposals of the Management Board and the Supervisory Board for agenda items 1 and 2 as stipulated in the invitation to the Extraordinary General Meeting made available for download at the website of the Company ([www.marinomed.com](http://www.marinomed.com)) as follows (please mark with a cross as applicable); without explicit instruction, the proxy holder will abstain from voting:

#### AGENDA ITEM 1 – Authorization to issue financial instruments

YES Vote	NO Vote	Abstention
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

#### AGENDA ITEM 2 – Conditional capital increase to service creditors of financial instruments

YES Vote	NO Vote	Abstention
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

The above-mentioned proxy holder is entitled and authorized to perform all actions and make all declarations free of the restrictions relating to dual representation.

The named proxy holder is empowered and authorized to carry out all actions and declarations under exemption from the restrictions of self-contracting and double representation.

#### Information on the protection of shareholder data

Marinomed Biotech AG processes personal data of its shareholders (including, but not limited to, those pursuant to Art. 10a para. 2 of the Austrian Stock Corporation Act (AktG), i.e. name, address, date of birth, securities deposit number, number of shares held by the shareholder, class of shares where

applicable, voting card number and, where applicable, name and date of birth of the authorized person(s)) on the basis of the applicable data protection provisions and the Austrian Stock Corporation Act (AktG), to enable the shareholders to exercise their rights at the General Meeting.

The processing of personal data of shareholders is an unconditional requirement for the attendance of the shareholders and their representatives at the General Meeting in accordance with the Austrian Stock Corporation Act (AktG). Consequently, Art. 6 (1) c) of the GDPR provides the legal basis for data processing.

The service providers retained for the purposes of organizing the General Meeting, will receive exclusively those personal data from Marinomed Biotech AG which are necessary to deliver the services for which they have been contracted, and they will process such data exclusively in accordance with the instructions of Marinomed Biotech AG.

At any time, each shareholder has the right of information, rectification, restriction, revocation and extinction regarding the processing of his/her personal data, as well as a right to data portability under chapter III of the GDPR. Personal data of shareholders will be deleted at the end of the legal retention period. Shareholders may exercise these rights free of charge by contacting Marinomed Biotech AG at the following contact details:

Marinomed Biotech AG  
Attn. Andreas Grassauer  
Hovengasse 25  
2100 Korneuburg  
Austria  
e-mail: [datenschutz@marinomed.com](mailto:datenschutz@marinomed.com)

Moreover, the shareholders have the right to file a complaint with the data protection authority in accordance with Art. 77 of the GDPR.

-----  
(Name/company and address of the shareholder in capital letters)

-----  
(Date, personal signature of the shareholder or facsimile of such signature)

-----  
(Custodian bank) / (Number of no-par value shares)

*Note:*  
*This is a working translation of the German language version and for convenience only. In the event of conflict with the German language version, the German language version shall prevail.*